Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.310
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Oramed Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Oramed Pharmaceuticals.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Oramed Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 9, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 20, 2024 |
Canaccord Genuity | Canaccord Genuity | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -13.42% | May 17, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 17, 2023 |
Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 12, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.07
from -0.48
EPS Next Year
n/a
from -0.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 |
---|---|
High | n/a |
Avg | n/a |
Low | n/a |
Revenue Growth
Revenue Growth | 2025 |
---|---|
High | - |
Avg | - |
Low | - |
EPS Forecast
EPS | 2025 |
---|---|
High | -0.07 |
Avg | -0.07 |
Low | -0.07 |
EPS Growth
EPS Growth | 2025 |
---|---|
High | - |
Avg | - |
Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.